TG Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
152.40
152.40
152.40
152.40
152.40
152
SG&A Expense
20,319.60
55,869.50
63,316.90
79,058.50
118,781.80
174,464
EBIT
20,168.40
55,721.10
63,180.00
78,969.10
118,711.80
174,400
Unusual Expense
503.40
720.00
1,029.50
995.70
786.10
939
Non Operating Income/Expense
108.90
95.40
-
283.50
844.80
878
Interest Expense
952.90
930.70
972.70
886.10
-
-
Pretax Income
20,478.20
55,781.30
62,948.60
78,252.90
118,476.00
173,482
Consolidated Net Income
20,478.20
55,781.30
62,948.60
78,252.90
118,476.00
173,482
Net Income
20,478.20
55,781.30
62,948.60
78,252.90
118,476.00
173,482
Net Income After Extraordinaries
20,478.20
55,781.30
62,948.60
78,252.90
118,476.00
173,482
Net Income Available to Common
20,478.20
55,781.30
62,948.60
78,252.90
118,476.00
173,482
EPS (Basic)
0.81
1.64
1.38
1.60
1.91
2.30
Basic Shares Outstanding
25,414.00
34,068.90
45,646.40
49,041.40
62,069.60
75,466.80
EPS (Diluted)
0.81
1.64
1.38
1.60
1.91
2.30
Diluted Shares Outstanding
25,414.00
34,068.90
45,646.40
49,041.40
62,069.60
75,466.80
EBITDA
20,167.30
55,717.20
63,164.60
78,906.20
118,629.40
174,312
Non-Operating Interest Income
30.80
55.00
174.70
323.00
294.50
857
About TG Therapeutics
View Profile
